Amgen is a large biotechnology company with a broad drug portfolio and an obesity-drug pipeline (MariTide). It trades on NASDAQ under the ticker AMGN, in the Biotechnology sector.
Key Facts
| Item | Details |
|---|---|
| Ticker | AMGN |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Headquarters | Thousand Oaks, CA, USA |
Bull Case & Risks
Bull Case
- A diversified biologics portfolio
- Obesity-pipeline optionality (MariTide)
- High dividend and cash flow
Risks
- Patent cliffs and biosimilar competition
- Pipeline clinical risk
Outlook
Amgen offers diversified biotech cash flows plus an obesity-drug call option in MariTide; patent cliffs and trial outcomes drive the story.
Educational information only, not investment advice. Stocks carry risk including possible loss of principal; past performance does not guarantee future results.